Financial Performance - Net revenue for Q3 2025 reached $222 million, a 15.2% year-over-year growth compared to $192.447 million in Q3 2024[9, 53] - Adjusted EBITDA for Q3 2025 was $26 million, representing an 11.6% margin, compared to $17.308 million and 9.0% margin in Q3 2024[9, 53] - The company's full year 2025 outlook projects net revenue between $871 million and $874 million, representing approximately 13% year-over-year growth[30] - Full year 2025 adjusted EBITDA is projected to be between $98 million and $101 million, with an approximate 11.4% margin[30] - Q4 2025 net revenue is expected to be between $211 million and $214 million, representing approximately 11-12% year-over-year growth[32] - Q4 2025 adjusted EBITDA is projected to be between $18 million and $21 million, with an approximate 9.2% margin[32] Business Operations - Warby Parker has 313 stores as of September 30, 2025, including 5 stores in Canada[7, 24] - The company opened 15 net new retail stores in Q3 2025[24] - Warby Parker estimates a potential footprint of 900+ stores[25] - The company estimates that its sales represent approximately 1% of the $68 billion U S eyewear market[7]

Financial Performance - B2 Cloud Storage revenue grew by 29% year-over-year in Q2 2025[11, 19, 33], accelerating from 23% growth in Q1 2025[11] - Total company revenue reached $36.3 million in Q2 2025, representing a 16% year-over-year increase[42] - The company's adjusted EBITDA margin doubled year-over-year[33, 61], reaching 18% in 1H 2025[44] - The company is targeting 30%+ B2 growth in Q4 2025[34, 35, 40] Customer Growth and Value - The number of customers with ARR (Annual Recurring Revenue) above $50,000 increased by 30% year-over-year[19, 20] - AI customers' data stored grew by 40x year-over-year[28] - The AI customer count increased by 70% year-over-year[28] - 3 of the top 10 customers are AI companies[28] Financial Strategy - The company secured a new $20 million line of credit[32, 33] - A stock buyback program of up to $10 million was approved[32, 33, 49, 50] - The company aims to reduce equity dilution by 15% to 25%[34]

Financial Performance - The company's ARR (Annual Recurring Revenue) reached $356 million as of 9/30/2025 [21] - Enterprise ARR constitutes 76% of the total ARR [21] - Non-GAAP Gross Margin was 79% in 3Q25 [22] - Non-GAAP Operating Income improved from a loss of $11 million in 3Q22 to an income of $8 million in 3Q25 [23] - Operating Cash Flow increased from a loss of $51 million in 3Q22 to an income of $11 million in 3Q25 [24] B2B and B2C Success Metrics - B2B customers experience an average increase of 13% in AOV (Average Order Value) [47] - B2B customers experience an average increase of 19% in return on ad spend [47] - B2C customers experience an average checkout conversion rate of 619% [52] - B2C customers experience an average increase of 15% in channel revenue [52] - B2C customers experience an average increase of 19% in return on ad spend [52]

Q3 2025 Earnings Report November 6, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future ev ...

9M and Q3 2025 Results Conference call and webcast for investors and analysts 6 November 2025 Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: 9M and Q3 2025 Results Conference call agenda | CEO Opening Remarks | Pascal Soriot Chief Executive Officer | | | --- | --- | --- | | Financial Res ...

This presentation contains certain "forward -looking statements" based on management's current expectations. Forward -looking stat ements include, but are not limited to, the statements under "Financial Outlook," statements regarding long term performance, statements regarding the Company's capital deployment plans, including anticipated annual dividend rates and share repurchase plans, and statements that can be identified by the use of forward -looking terminology such as "may," "can," "if," "continue," " ...

Disclaimer Unless the context otherwise provides, "we," "us," "our," "CRH", the "Company" and like terms refer to CRH plc and its consolidated subsidiaries. Forward-Looking Statements In order to rely upon the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, CRH is providing the following cautionary statement. This presentation contains statements that are, or may be deemed to be, forward-looking statements with respect to the financial condition, results of op ...

Financial Performance - Revenue increased by 1.3% year-over-year to $6,049 million[12] - Adjusted EBITDA increased by 1.5% year-over-year to $2,762 million[12] - Adjusted EPS increased by 5.3% to $0.79[12] - Free cash flow increased by 20.6% to $1,003 million[14] - Capital expenditures decreased by 6.6% year-over-year to $891 million[12] Subscriber Metrics - Postpaid churn rate improved by 15 bps year-over-year[6] - Retail FTTH Internet net additions were 65,239[9] - Crave subscribers increased by 24% year-over-year to 4.3 million[9] Bell Media - Bell Media revenue decreased by 6.4% year-over-year to $732 million[23] - Bell Media adjusted EBITDA decreased by 6.7% year-over-year to $237 million[24] Bell CTS U.S.(Ziply Fiber) - Bell CTS U.S revenue was $160 million for the 2-month period from August 1, 2025 through September 30, 2025[18] - Bell CTS U.S adjusted EBITDA was $71 million for the 2-month period from August 1, 2025 through September 30, 2025[18]

Financial Performance - FY25 revenue reached $21.84 billion, with adjusted FXN growth of 7.7% and organic growth of 2.9%[16,44] - Adjusted diluted EPS for FY25 was $14.40, a 9.6% year-over-year increase[16] - Adjusted operating margin for FY25 was 25.0%, an increase of 80 bps year-over-year[16] - The company returned $2.2 billion to shareholders through share repurchases and dividends[16,48] - Free cash flow for FY25 was $2.67 billion, a 14% decrease compared to FY24's $3.119 billion[47] Segment Performance (Q4 FY25) - BD Medical segment revenue was $3.155 billion, with a 9.9% FXN increase[34] - BD Life Sciences segment revenue was $1.368 billion, with a 0.3% FXN increase[36] - BD Interventional segment revenue was $1.367 billion, with a 7.5% FXN increase[39] FY26 Guidance - The company expects low single-digit revenue growth (FXN) for FY26, including a ~90 bps FX tailwind[53] - Adjusted diluted EPS for FY26 is projected to be between $14.75 and $15.05, a 2.4% to 4.5% increase[53]

Financial Performance - Total revenues for Q3 2025 increased by 30% to US$97.3 million[13, 43] - RUCONEST® revenues in Q3 2025 reached US$82.2 million[13, 22] - Joenja® revenues in Q3 2025 amounted to US$15.1 million[13, 27] - Operating profit significantly grew to US$16.0 million in Q3 2025[13, 43] - Cash flow from operations was US$32 million in Q3 2025[14, 41] - Total revenues for 9M 2025 grew 33% to US$269.6 million[44, 45] Business Updates and Outlook - 2025 revenue guidance raised to US$365-375 million due to strong RUCONEST® performance[14, 51] - RUCONEST® U S volume growth was +24% in 3Q25 and +28% in 9M25[22] - There are 116 US patients on Joenja® representing a +25% increase vs 3Q24[27] - FDA filing for Leniolisib for 4-11 year old APDS patients is based on Phase III data and has a PDUFA date of Jan 31, 2026[28]